Hologic, Inc. (NASDAQ:HOLX) Shares Bought by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC grew its holdings in Hologic, Inc. (NASDAQ:HOLX) by 22.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,598 shares of the medical equipment provider’s stock after buying an additional 1,191 shares during the period. Sequoia Financial Advisors LLC’s holdings in Hologic were worth $471,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. McGlone Suttner Wealth Management Inc. acquired a new position in Hologic during the fourth quarter worth $27,000. Venturi Wealth Management LLC acquired a new position in shares of Hologic during the 3rd quarter valued at about $29,000. NBC Securities Inc. purchased a new stake in shares of Hologic in the third quarter valued at about $33,000. Bartlett & CO. Wealth Management LLC acquired a new stake in Hologic during the fourth quarter worth about $33,000. Finally, Deseret Mutual Benefit Administrators raised its stake in Hologic by 42.2% during the third quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 155 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Down 0.3 %

Shares of NASDAQ HOLX opened at $74.92 on Thursday. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $87.88. The company has a market capitalization of $17.59 billion, a price-to-earnings ratio of 35.51, a price-to-earnings-growth ratio of 2.62 and a beta of 1.00. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. The business has a 50-day moving average of $75.68 and a two-hundred day moving average of $72.48.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $989.32 million. During the same quarter in the previous year, the business earned $1.07 earnings per share. The firm’s revenue was down 5.7% compared to the same quarter last year. On average, analysts forecast that Hologic, Inc. will post 4.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several analyst reports. Raymond James increased their price target on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. William Blair reissued an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. StockNews.com lowered Hologic from a “buy” rating to a “hold” rating in a research note on Friday, March 8th. Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Hologic in a research report on Wednesday, April 10th. Finally, UBS Group upped their target price on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. Six research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Hologic currently has an average rating of “Hold” and an average target price of $87.00.

Insider Activity at Hologic

In related news, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now directly owns 1,572 shares of the company’s stock, valued at $119,802.12. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the transaction, the director now owns 1,572 shares of the company’s stock, valued at $119,802.12. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the sale, the director now directly owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The disclosure for this sale can be found here. Insiders have sold 32,846 shares of company stock valued at $2,473,443 in the last ninety days. Insiders own 1.75% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.